Vitamin D supplementation and acute kidney injury in patients on haemodialysis: A retrospective cohort study
Published
January 10, 2024
Paper ID
PAP-000146
Status
Published
DOI
10.65712/tmj.test000404
Advance Services
Abstract
Background: Guidelines make only a weak recommendation on vitamin D supplementation. Methods: Eligible participants were patients on haemodialysis. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.74 (95% CI 0.27 to 0.84). Conclusion: These findings suggest that vitamin D supplementation is associated with better acute kidney injury in patients on haemodialysis.
References
1. Lindqvist O, Mensah Z, et al. SGLT2 inhibitors and chronic pain scores. N Engl J Med. 2017;293(11):519-908.
2. Moreau A, Costa U, et al. Machine-learning triage and glycaemic control. Crit Care Med. 2009;224(9):551-1150.
3. Costa R, Kowalski U, et al. Point-of-care ultrasound and 30-day readmission. BMJ. 2025;195(8):691-1067.
4. Okafor R, Ibrahim N, et al. High-flow nasal oxygen and surgical site infection. BMC Med. 2012;111(8):633-1797.
5. Patel Y, Okafor W, et al. Early mobilisation and glycaemic control. Diabetes Care. 2013;273(6):81-1546.
Introduction
acute kidney injury remains a leading cause of avoidable harm among patients on haemodialysis. Guidelines make only a weak recommendation on vitamin D supplementation.
acute kidney injury remains a leading cause of avoidable harm among patients on haemodialysis.
Materials and Methods
We conducted a retrospective cohort study across 1 centres between 2019 and 2025. The primary outcome was acute kidney injury, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. Eligible participants were patients on haemodialysis.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was acute kidney injury, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. acute kidney injury occurred in 20% of the intervention group versus 25% of controls.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Female | 609 | 56 | 16.0 | 0.62 | 0.28–1.28 |
| Age ≥ 65 | 84 | 55 | 17.7 | 0.40 | 0.28–1.1 |
| Control | 410 | 92 | 25.4 | 0.53 | 0.43–1.38 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.60 (95% CI 0.43 to 0.66). Serious adverse events were rare and similar between groups. acute kidney injury occurred in 11% of the intervention group versus 19% of controls.
Discussion
Future work should test vitamin D supplementation in a pragmatic multicentre trial. These findings suggest that vitamin D supplementation is associated with better acute kidney injury in patients on haemodialysis.
Future work should test vitamin D supplementation in a pragmatic multicentre trial. Residual confounding cannot be excluded. These findings suggest that vitamin D supplementation is associated with better acute kidney injury in patients on haemodialysis.
These findings suggest that vitamin D supplementation is associated with better acute kidney injury in patients on haemodialysis. Future work should test vitamin D supplementation in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Conclusions
Vitamin D supplementation is a reasonable option for patients on haemodialysis to improve acute kidney injury.
Appendices
Supplementary tables are available on request.